Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 345

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 8
Chunk 345
---
, depreciation and amortization and non-cash operating lease cost, gain on derivative liabilities, and changes in operating assets and liabilities that provided $54.9 million of cash.

For the nine months ended September 30, 2023, net cash used for operating activities was approximately $15.3 million, attributable to our net loss of $92.9 million, partially offset by other non-cash reconciling items of $20.3 million related to loss on derivative liabilities, stock-based compensation, change in fair value of debt and liability instruments, depreciation and amortization and non-cash operating lease cost, and changes in operating assets and liabilities that provided $57.3 million of cash.

Cash Flows from Investing Activities

For the nine months ended September 30, 2024, net cash used for investing activities was approximately $2.5 million and is primarily related to the $2.0 million purchase of Denali shares and $0.5 million related to payments of deferred consideration for the Romeg intangible asset acquisition under that certain license agreement, dated as of June 14 2022, by and between the Company and Romeg (the “Romeg License Agreement”).

For the nine months ended September 30, 2023, net cash used for investing activities was approximately $0.2 million, related to payments of deferred consideration for the Romeg intangible asset acquisition under the Romeg License Agreement.

Cash Flows from Financing Activities

For the nine months ended September 30, 2024, net cash used for financing activities was approximately $10.9 million and was primarily related to $93.4 million in gross proceeds from the Revolving Facility, $25.0 million in gross proceeds from issuance of shares under the Bought Deal Offering and Registered Direct Offering, $10.0 million in proceeds from receiving the FSF Deposit, $0.2 million in proceeds from the Standby Equity Purchase Agreements and $0.9 million in proceeds from the exercise of stock options and warrants and ESPP, offset by the $137.3 million repayment of borrowings under the Revolving Facility, Oramed Note, and Convertible Debentures, the $2.8 million payment of transaction costs related to the Bought Deal Offering and Registered Direct Offering and $0.3 million cash consideration paid in connection with the repurchase of certain portion of the SPAC Warrants.

For the nine months ended September 30, 2023, net cash provided by financing activities was approximately $15